- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01201746
Influence of Periodontal Treatment on Systemic Inflammatory Mediators (Perio-CHD)
Influence of Periodontal Treatment on Systemic Inflammatory Mediators:hsC-reactive Protein, Fibrinogen and White Blood Cells in CHD Patients
Currently the research issue in establishing the role of periodontal disease (PD) in coronary heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship between PD and CHD. There is no consensus on definition of a periodontal disease case or the threshold level that may give clear indication for this relationship. Periodontal therapy has been used in different studies with the hope that a change in periodontal disease status may modify the factors associated with CHD risk. Many of these studies, on role of periodontal therapy in the reduction of CHD associated risk-factors, were based on small study samples, and very few studies were randomized controlled trials. So a need for large prospective studies is warranted in literature.----------- A single-blind parallel-arm randomized controlled clinical trial was designed to observe the influence of periodontal treatment on serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD patients.
Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may decrease the host systemic inflammatory burden associated with atherogenic processes.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Punjab
-
Lahore, Punjab, 파키스탄, 54300
- Punjab Institute of Cardiology
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
A. General/Medical
- Any race/ethnic group
- Aged > 30 years
- Male or female
- CHD case (CHD angiographically confirmed)
- CHD diagnosed > 3 months prior to entry into study.
- No acute or chronic systemic conditions (see exclusion criteria below)
- No medications/medication history that can interfere with the study (see exclusion criteria below)
- Non-smoker (=Never smoker) or former smoker (=Does not smoke now and has not smoked at all for a minimum of the last 12 consecutive months)
- Able and willing to comply with study procedures
- Able and willing to be available for the duration of the study
- Able and willing to provide signed informed consent
B. Oral/Periodontal
- Dentate with at least 14 natural teeth, excluding third molars, that can be evaluated periodontally.
- Baseline whole mouth BOP > 20% of sites.
- Periodontitis case; periodontitis case defined as subject having ≥ 4 teeth with ≥ 1 site with PPD ≥ 4 mm & CAL ≥ 3 mm at same site
- No mechanical periodontal therapy in the last 6 months.
- No acute oral diseases (mucosal lesions), oral infections, need for immediate dental/periodontal care (e.g., NUG).
Exclusion Criteria:
A. General/Medical
- Age ≤ 30 years
- Not fulfilling criteria of defined CHD case
- Fulfilling criteria of defined CHD case, but diagnosed ≤ 3 months prior to start of study
- Current smoker
- Former smoker who does not smoke but who has smoked ≥ 1 cigarette (or equivalent, in form of water pipe, pipe, cigar) in the last 12 months.
- Females pregnant or lactating
- Systemic chronic conditions known to be associated with periodontitis or with changes in systemic inflammation: Diabetes,Rheumatoid Arthritis, Rheumatic Fever, SLE, Malignancy, Respiratory diseases, Renal diseases, Other (e.g., autoimmune diseases, fungal infections, immunological deficiencies, etc.)
- Systemic acute conditions known to affect systemic markers of inflammation: Acute bacterial infection, Acute viral infection (common cold, influenza, sinusitis), Orthopedic trauma, Surgery
- Medications known to affect systemic inflammatory biomarkers: Statins, Systemic steroids, Non-steroidal anti-inflammatory drugs, Immunosuppressants,
- Medications potentially affecting systemic inflammatory markers, if therapy started less than 3 months prior to study such as Hormone replacement therapy, Contraceptives
- Systemic antibiotic therapy in the last 3 months
- Unable or unwilling to comply with study procedures
- Unable or unwilling to be available for the duration of the study
- Unable or unwilling to provide signed informed consent
B. Oral/Periodontal
- <14 teeth that can be periodontally evaluated (excluding 3rd molars)
- BOP ≤ 20% of sites
- Not fulfilling criteria of defined periodontitis case
- Having received any periodontal therapy within last 6 months
- Topical/local antibiotic or anti-inflammatory therapy in last 6 months
- Acute oral infections
- Oral wounds, including recent (< 2 months) extractions
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Periodontal Therapy
Scaling Root planing and oral hygiene instructions
|
Scaling, root planning and oral hygiene instructions
다른 이름들:
|
|
위약 비교기: Delayed treatment
Scaling Root planing and oral hygiene instructions
|
Scaling, Root Planing and oral hygiene instruction
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
high-sensitivity C-Reactive Protein (hsCRP)
기간: 1-3 months
|
1-3 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Fibrinogen
기간: 1-3 months
|
1-3 months
|
|
White Blood Cells
기간: 1-3 months
|
1-3 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Ayyaz A Khan, Ph.D., Sheikh Zayed Federal Postgraduate Medical Institute
- 수석 연구원: Syed Akhtar H Bokhari, MCPS, Sheikh Zayed Federal Postgraduate Medical Institute
- 연구 의자: Mohammad Azhar, MRCP, Punjab Institute of Cardiology
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
관상 동맥 심장 질환에 대한 임상 시험
-
Fondation Hôpital Saint-Joseph모병
-
Chinese Academy of Medical Sciences, Fuwai HospitalMedtronic; CCRF Consulting Co., Ltd.빼는Transradial-transfemoral Coronary Interventions 비교
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.알려지지 않은심장 또는 뇌혈관 질환 무료 요금 | Transradial-transfemoral Coronary Interventions 비교중국
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus University 그리고 다른 협력자들종료됨심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.아직 모집하지 않음Crohn & amp;#39; s | Crohn & amp;#39; s Disease (CD)
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of Health모집하지 않고 적극적으로
Periodontal therapy에 대한 임상 시험
-
Recep Tayyip Erdogan University Training and Research...모병
-
Johns Hopkins University아직 모집하지 않음
-
Baskent University아직 모집하지 않음경요도 절제술(TUR) 증후군
-
Foundation University Islamabad모병
-
Philadelphia University, Jordan모병뇌성마비(CP) | 웅크린 걸음걸이 | 근육 약화 | 인내심 있는 | Diaplegia | 전방 골반 경사요르단